Related references
Note: Only part of the references are listed.Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review
Lynda Kwon Beaupin et al.
LEUKEMIA & LYMPHOMA (2017)
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia
Nobuko Hijiya et al.
LEUKEMIA & LYMPHOMA (2016)
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
Inge M. van der Sluis et al.
HAEMATOLOGICA (2016)
The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience
Muaz Alrazzak et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2016)
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus
Kjeld Schmiegelow et al.
LANCET ONCOLOGY (2016)
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation
Inge M. van der Sluis et al.
HAEMATOLOGICA (2016)
Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model
Chengcheng Liu et al.
PLOS ONE (2016)
Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report
Richard H. Ko et al.
CANCER (2015)
Still trying to pick the best asparaginase preparation
Carmelo Rizzari
LANCET ONCOLOGY (2015)
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial
Andrew E. Place et al.
LANCET ONCOLOGY (2015)
Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002
A. Karachunskiy et al.
LEUKEMIA (2015)
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring
Barbara Asselin et al.
LEUKEMIA & LYMPHOMA (2015)
Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review
Lesleigh S. Abbott et al.
PEDIATRIC DRUGS (2015)
PEG-Asparaginase Allergy in Children With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Protocol
Louise Tram Henriksen et al.
PEDIATRIC BLOOD & CANCER (2015)
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia
Wing H. Tong et al.
BLOOD (2014)
Comparison of Allergic Reactions to Intravenous and Intramuscular Pegaspargase in Children with Acute Lymphoblastic Leukemia
William C. Petersen et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2014)
Optimizing asparaginase therapy for acute lymphoblastic leukemia
Carmelo Rizzari et al.
CURRENT OPINION IN ONCOLOGY (2013)
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01
Lynda M. Vrooman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Immediate Cooling Does Not Prevent the Ex Vivo Hydrolysis of L-Asparagine by Asparaginase
Claudia Lanvers-Kaminsky et al.
THERAPEUTIC DRUG MONITORING (2013)
Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia
Reid Merryman et al.
PEDIATRIC BLOOD & CANCER (2012)
L-Asparaginase Treatment in Acute Lymphoblastic Leukemia
Rob Pieters et al.
CANCER (2011)
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)
L. B. Silverman et al.
LEUKEMIA (2010)
Therapeutic Drug Monitoring of Asparaginase in the ALL-BFM 2000 Protocol Between 2000 and 2007
Dominik Schrey et al.
PEDIATRIC BLOOD & CANCER (2010)
Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia
A. Karachunskiy et al.
LEUKEMIA (2008)
Intensified PEG-L-asparaginase and anti metabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia - A report from the Children's Oncology Group
Wanda L. Salzer et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2007)
Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia
Umesh K. Narta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia
A Pession et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients:: results of DCLSG protocol ALL-8 (1991-1996)
WA Kamps et al.
LEUKEMIA (2002)
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies:: results of a randomized European Organisation for Research and Treatment of Cancer -: Children's Leukemia Group phase 3 trial
M Duval et al.
BLOOD (2002)
Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries
BK Albertsen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment:: Results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study -: A report from the Associazione Italiana Ematologia Oncologia Pediatrica
C Rizzari et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995
M Schrappe et al.
LEUKEMIA (2000)
L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E-coli L-asparaginase as first exposure
C Rizzari et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
